Biomea Fusion

We are a biopharmaceutical company focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure and the ability to drive a deeper, more durable response. We are utilizing our proprietary FUSION™ System to discover, design and develop a pipeline of next-generation covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Our lead product candidate, BMF-219, is an orally bioavailable, potent and selective covalent inhibitor of menin, an important transcriptional regulator known to play a direct role in in regulating the growth of beta cells in the pancreas as well as oncogenic signaling in multiple cancers. Beyond BMF-219, we are utilizing our novel platform to develop treatments against other high-value metabolic diseases and oncogenic drivers of cancer. We entered the clinic with our second development candidate, BMF-500, a covalent inhibitor of FLT3 and are studying BMF-500 in acute leukemia patients. We also announced our third development candidate, an oral, small molecule GLP-1 receptor agonist in obesity. All our molecules, BMF-219, BMF-500, and our GLP-1 receptor agonist were developed in-house by the Biomea team. We aim to have an outsized impact on the treatment of disease for the patients we serve. We aim to cure. The name biomea derives from the Greek word bios, meaning “life,” and the Latin word mea, meaning “my.” At Biomea Fusion, we develop medicines to improve the life of the individual. Visit us at biomeafusion.com